Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia

Core-binding factor (CBF) acute myeloid leukemia (AML), defined by the presence of the RUNX1::RUNX1T1 or CBFB::MYH11 fusion genes, constitutes approximately 15% of all cases of newly diagnosed AML ...